0.9601
price down icon7.68%   -0.0799
 
loading
Unity Biotechnology Inc stock is traded at $0.9601, with a volume of 268.95K. It is down -7.68% in the last 24 hours and down -43.85% over the past month. Unity Biotechnology Inc designs therapeutics that prevent, halt, and reverse various diseases of aging. The company focuses on clearing senescent cells, and creating senolytic medicines. Its medicines target vulnerabilities to senescent cells to clear those cells from the human body while leaving normal cells unaffected. The firm focuses on age-associated diseases such as osteoarthritis, eye diseases, and pulmonary diseases. Its drug candidates include, UBX1325 is being developed for age-related diseases of the eye, including diabetic macular edema, or DME, UBX2089, which is a circulating hormone which is produced in the kidneys and choroid plexus of the brain, which is being researched for multiple neurology indications, and UBX2050.
See More
Previous Close:
$1.04
Open:
$1.05
24h Volume:
268.95K
Relative Volume:
1.01
Market Cap:
$16.19M
Revenue:
-
Net Income/Loss:
$-52.53M
P/E Ratio:
-0.2623
EPS:
-3.66
Net Cash Flow:
$-39.93M
1W Performance:
-24.10%
1M Performance:
-43.85%
6M Performance:
-33.33%
1Y Performance:
-42.16%
1-Day Range:
Value
$0.95
$1.06
1-Week Range:
Value
$0.95
$1.27
52-Week Range:
Value
$0.9397
$3.10

Unity Biotechnology Inc Stock (UBX) Company Profile

Name
Name
Unity Biotechnology Inc
Name
Phone
(650) 416-1192
Name
Address
285 EAST GRAND AVENUE, SOUTH SAN FRANCISCO, CA
Name
Employee
16
Name
Twitter
@unitybiotech
Name
Next Earnings Date
2024-11-11
Name
Latest SEC Filings
Name
UBX's Discussions on Twitter

Compare UBX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
UBX
Unity Biotechnology Inc
0.9601 16.19M 0 -52.53M -39.93M -3.66
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
484.74 124.48B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
617.00 67.45B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
567.09 34.59B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
255.76 33.10B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
271.04 29.15B 3.81B -644.79M -669.77M -6.24

Unity Biotechnology Inc Stock (UBX) Upgrades & Downgrades

Date Action Analyst Rating Change
Aug-22-24 Initiated Rodman & Renshaw Buy
Nov-16-23 Upgrade Wedbush Neutral → Outperform
Jan-04-22 Upgrade ROTH Capital Neutral → Buy
Nov-10-21 Upgrade Mizuho Neutral → Buy
Jun-28-21 Upgrade Citigroup Sell → Buy
Jun-07-21 Initiated H.C. Wainwright Buy
Feb-16-21 Downgrade Citigroup Neutral → Sell
Aug-18-20 Downgrade Citigroup Buy → Neutral
Aug-18-20 Downgrade Mizuho Buy → Neutral
Aug-18-20 Downgrade Morgan Stanley Overweight → Equal-Weight
Aug-17-20 Downgrade ROTH Capital Buy → Neutral
Jul-28-20 Initiated ROTH Capital Buy
Dec-12-19 Initiated Cantor Fitzgerald Overweight
Mar-07-19 Initiated Cantor Fitzgerald Overweight
Sep-07-18 Initiated Mizuho Buy
May-29-18 Initiated Citigroup Buy
May-29-18 Initiated Goldman Neutral
May-29-18 Initiated Morgan Stanley Overweight
View All

Unity Biotechnology Inc Stock (UBX) Latest News

pulisher
Mar 28, 2025

What is HC Wainwright’s Estimate for UBX FY2026 Earnings? - Defense World

Mar 28, 2025
pulisher
Mar 26, 2025

Unity Biotechnology (NASDAQ:UBX) Price Target Lowered to $4.00 at Chardan Capital - Defense World

Mar 26, 2025
pulisher
Mar 25, 2025

H.C. Wainwright cuts Unity Biotechnology target to $4; keeps buy rating - Investing.com Australia

Mar 25, 2025
pulisher
Mar 25, 2025

UBX Stock Down 29% on Mixed Results From Phase II Eye Disease Study - MSN

Mar 25, 2025
pulisher
Mar 25, 2025

Unity Biotechnology price target lowered to $4 from $6 at Chardan - TipRanks

Mar 25, 2025
pulisher
Mar 25, 2025

H.C. Wainwright cuts Unity Biotechnology target to $4; keeps buy rating By Investing.com - Investing.com South Africa

Mar 25, 2025
pulisher
Mar 25, 2025

UNITY Biotechnology tanks on mixed results for eye disease drug - The Pharma Letter

Mar 25, 2025
pulisher
Mar 25, 2025

Mizuho maintains Unity Biotechnology Outperform rating By Investing.com - Investing.com South Africa

Mar 25, 2025
pulisher
Mar 25, 2025

Chardan Cuts Price Target on Unity Biotechnology to $4 From $6, Keeps Buy Rating - Marketscreener.com

Mar 25, 2025
pulisher
Mar 25, 2025

Mizuho maintains Unity Biotechnology Outperform rating - Investing.com India

Mar 25, 2025
pulisher
Mar 25, 2025

Unity Biotechnology (NASDAQ:UBX) Price Target Cut to $4.00 by Analysts at HC Wainwright - Defense World

Mar 25, 2025
pulisher
Mar 24, 2025

UNITY Biotechnology to Host Virtual Investor Event to Discuss 24- and 36-Week Data from the Phase 2b ASPIRE - EIN News

Mar 24, 2025
pulisher
Mar 24, 2025

Sector Update: Health Care Stocks Rise Late Afternoon - TradingView

Mar 24, 2025
pulisher
Mar 24, 2025

Sector Update: Health Care - TradingView

Mar 24, 2025
pulisher
Mar 24, 2025

Unity Biotechnology Shares Decline After Diabetic Edema Treatment Misses Primary Endpoint - Marketscreener.com

Mar 24, 2025
pulisher
Mar 24, 2025

UNITY Biotechnology tanks after failing to meet goal in eye disorder treatment trial - MSN

Mar 24, 2025
pulisher
Mar 24, 2025

HC Wainwright Adjusts Unity Biotechnology Price Target to $4 From $8, Maintains Buy Rating - Marketscreener.com

Mar 24, 2025
pulisher
Mar 24, 2025

UNITY Biotechnology Shares Drop 33% After Phase 2b Trial Data on UBX1325 in Diabetic Macular Edema - Yahoo Finance

Mar 24, 2025
pulisher
Mar 24, 2025

Unity Biotechnology Unveils Mixed Data From Study For Diabetes-Related Blindness, Stock Falls - Benzinga

Mar 24, 2025
pulisher
Mar 24, 2025

Unity Biotechnology, Inc. Announces Topline Results from the ASPIRE Phase 2B Study in Diabetic Macular Edema - Marketscreener.com

Mar 24, 2025
pulisher
Mar 24, 2025

UNITY Biotechnology Announces Topline Results from the ASPIRE Phase 2b Study in Diabetic Macular Edema - GlobeNewswire

Mar 24, 2025
pulisher
Mar 24, 2025

New DME Treatment Matches Standard Care: Phase 2b Shows Promising Vision Gains - Stock Titan

Mar 24, 2025
pulisher
Mar 24, 2025

Positive Outlook for Unity Biotechnology Despite Initial Setback in UBX1325 Study - TipRanks

Mar 24, 2025
pulisher
Mar 23, 2025

China’s Plans for a $900 Billion Space Project, but Can It Catch Up to SpaceX? - The Globe and Mail

Mar 23, 2025
pulisher
Mar 23, 2025

UNITY Biotechnology to Host Virtual Investor Event Featuring Phase 2b ASPIRE Study Results for UBX1325 in Diabetic Macular Edema - Nasdaq

Mar 23, 2025
pulisher
Mar 23, 2025

UNITY Biotechnology to Host Virtual Investor Event to - GlobeNewswire

Mar 23, 2025
pulisher
Mar 23, 2025

Key Phase 2b Data Coming: UNITY's DME Treatment Could Transform Eye Disease Care - Stock Titan

Mar 23, 2025
pulisher
Mar 22, 2025

Where Will QuantumScape Stock Be in 3 Years? - The Globe and Mail

Mar 22, 2025
pulisher
Mar 20, 2025

This Micro Cap Continues This Week's Dominance Amid New CEO Appointment - The Globe and Mail

Mar 20, 2025
pulisher
Mar 20, 2025

RECONAFRICA ANNOUNCES ACCELERATION OF DRILLING INTO Q2 2025 AND A CORPORATE UPDATE - The Globe and Mail

Mar 20, 2025
pulisher
Mar 19, 2025

3 Reasons to Avoid AIR and 1 Stock to Buy Instead - The Globe and Mail

Mar 19, 2025
pulisher
Mar 17, 2025

This Media Stock Is Finding Serious Success Prior To Opening Bell - The Globe and Mail

Mar 17, 2025
pulisher
Mar 16, 2025

Unity Biotechnology Reports 2024 Financial Results and Updates - MSN

Mar 16, 2025
pulisher
Mar 15, 2025

Unity Biotechnology announces upcoming trial data and new board of directors member - Ophthalmology Times

Mar 15, 2025
pulisher
Mar 14, 2025

Chardan Capital Has Bullish Outlook for UBX FY2025 Earnings - Defense World

Mar 14, 2025
pulisher
Mar 13, 2025

HC Wainwright Has Strong Estimate for UBX FY2025 Earnings - Defense World

Mar 13, 2025
pulisher
Mar 12, 2025

Analysts Issue Forecasts for UBX Q1 Earnings - Defense World

Mar 12, 2025
pulisher
Mar 11, 2025

Unity Biotechnology (NASDAQ:UBX) Receives “Buy” Rating from Chardan Capital - Defense World

Mar 11, 2025
pulisher
Mar 10, 2025

UNITY Biotechnology appoints Yehia Hashad to its board -March 10, 2025 at 10:40 am EDT - Marketscreener.com

Mar 10, 2025
pulisher
Mar 10, 2025

Unity Biotechnology Appoints Dr. Yehia Hashad to Board - TipRanks

Mar 10, 2025
pulisher
Mar 10, 2025

UNITY Biotechnology Appoints Industry Leader and - GlobeNewswire

Mar 10, 2025
pulisher
Mar 10, 2025

UNITY Biotech Strengthens Board with CMO Appointment Before Key Trial Results - StockTitan

Mar 10, 2025
pulisher
Mar 10, 2025

Buy Rating Reaffirmed for Unity Biotechnology Amid Promising Developments in DME Treatment - TipRanks

Mar 10, 2025
pulisher
Mar 07, 2025

Unity Biotechnology reports Q4 EPS (50c) vs. (28c) last year - TipRanks

Mar 07, 2025
pulisher
Mar 07, 2025

UNITY Biotechnology Reports Q4 and Full Year 2024 Financial Results and Anticipates ASPIRE Study Data on UBX1325 for Diabetic Macular Edema - Nasdaq

Mar 07, 2025
pulisher
Mar 07, 2025

Unity Biotechnology, Inc. SEC 10-K Report - TradingView

Mar 07, 2025
pulisher
Mar 07, 2025

UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates - GlobeNewswire

Mar 07, 2025
pulisher
Feb 20, 2025

Canadian Investment Regulatory Organization Trading HaltRCK - The Globe and Mail

Feb 20, 2025
pulisher
Feb 11, 2025

Korro Bio CFO takes medical leave, interim officers appointed - Investing.com

Feb 11, 2025
pulisher
Feb 07, 2025

Annovis Bio (NYSE: ANVS) CEO to Present at Oppenheimer Healthcare Conference - The Globe and Mail

Feb 07, 2025
pulisher
Feb 06, 2025

Unity Biotechnology CEO Anirvan Ghosh sells shares worth $1,431 - MSN

Feb 06, 2025

Unity Biotechnology Inc Stock (UBX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$67.94
price down icon 3.89%
$72.00
price down icon 5.62%
$31.17
price up icon 0.13%
$18.80
price down icon 2.54%
$90.29
price down icon 0.85%
biotechnology ONC
$271.04
price down icon 0.42%
Cap:     |  Volume (24h):